Core Points - The company has completed the change registration of its "Drug Production License" and obtained the new license from the Hunan Provincial Drug Administration [1][2] - The changes include the addition of new production ranges for tablets and raw materials, as well as the acceptance of commissioned production for specific products [1][3] - The new license will not significantly impact the company's existing production structure or current performance [3] Summary of Changes - The production address at 789 Lushong Road, Changsha, Hunan, has added a new production range for tablets, which will only be used for registration purposes [1] - The raw material production facility at 368 Huanglong Road, Tongguan Town, has added new raw materials for registration, including Remdesivir and others [1] - The company will produce Huangtengsu dispersible tablets and Jingangteng dispersible tablets under commission from Hunan Xiangya Pharmaceutical Co., Ltd. [1] - The company will also produce Yinhuang granules under commission from Hunan Ruixin Pharmaceutical Co., Ltd. [1] Impact on the Company - The changes in the "Drug Production License" will not affect the company's existing production capacity, which will remain stable [3] - The company does not expect any significant impact on its current performance due to the new license [3] Product Inclusion in National Medical Insurance - The company's product, Yinxue Qufeng Zhitong Granules, has been included in the 2025 National Medical Insurance Directory, which is expected to enhance its market promotion and sales potential [5][7] - This product is based on a traditional Chinese medicine formula and has not yet been officially launched for sale [6][7] - The company aims to strengthen its position in the market by increasing investment in the research and development of innovative Chinese medicine products [7]
湖南方盛制药股份有限公司 关于公司《药品生产许可证》变更的公告